What is the market's earnings forecast for CNO Financial Group next quarter?

What is CNO Financial Group's gross profit margin?

Did CNO Financial Group beat or miss consensus estimates last quarter?

What does CNO Financial Group do and what are its main business segments?

What were the key takeaways from CNO Financial Group's earnings call?

What were the key takeaways from CNO Financial Group’s earnings call?

What guidance did CNO Financial Group's management provide for the next earnings period?

What is CNO Financial Group's latest dividend and current dividend yield?

- **Record Growth and Profitability**: 15% NAP growth, 11.4% ROE, and $386M shareholder returns highlight 2025 success.
- **Medicare Shift**: Medicare Supplement NAP up 49% annually, driven by consumer preference and higher cross-sell potential.
- **ROE Target Progress**: 2026 EPS guidance of $4.25-$4.45 reflects 8% growth, with 12% ROE target by 2027.
- **Investment Discipline**: 12+ quarters of >6% new money yields, $31B high-quality portfolio, and cautious risk-taking in alternatives.
- **Macroeconomic Resilience**: Agent productivity focus and demographic tailwinds offset economic headwinds.

**【Management Opening Remarks】**
- Adam Auvil highlighted the company's strong performance in 2025, emphasizing record sales, improved profitability, and capital deployment. He noted the availability of the earnings release and reminded participants of forward-looking statements and non-GAAP reconciliations.

**【CEO Summary Section】**
- **Record Growth**: Full-year total new annualized premium (NAP) up 15%, with double-digit growth across life, health, and annuities. Medicare Supplement NAP rose 49% annually and 92% quarterly, driven by consumer preference shifts from Medicare Advantage.
- **Distribution Strength**: 14th consecutive quarter of sales growth, 12th quarter of producing agent count growth, and record agent productivity. Brokerage and advisory client assets exceeded $5 billion.
- **Strategic Focus**: Emphasis on middle-income market and captive agent model as competitive advantages. 2025 marked the third consecutive year of record Bankers Life production.
- **Capital Deployment**: Returned $386 million to shareholders, including a 13th consecutive dividend increase. Book value per share grew at a 7% CAGR over three years.

**【CFO Financial Commentary】**
- **Financial Performance**: Operating ROE (excluding significant items) improved to 11.4% vs. 10% in 2024, with EPS up 10% quarterly and 6% annually. Expense ratio of 18.9% beat guidance, driven by operating leverage.
- **Investment Results**: Net investment income (NII) up 6% annually, with new money rates exceeding 6% for 12 consecutive quarters. Total invested assets reached $31 billion, 97% rated investment-grade.
- **Capital Position**: Consolidated RBC ratio of 380%, well within 360%-390% target range. Free cash flow of $200-$250 million in 2026 will support growth and strategic initiatives.
- **2026 Guidance**: Target EPS of $4.25-$4.45 (8% midpoint growth), expense ratio of 18.8%-19.2%, and continued ROE improvement toward 12% by 2027.

**【Q&A Key Highlights】**
- **Sales Lag and ROE Emergence**: CFO noted immediate margin capture on new business, with ROE improvement driven by sustained sales momentum and disciplined capital deployment.
- **Macroeconomic Impact**: CEO acknowledged headwinds from layoffs and economic uncertainty but emphasized long-term demographic tailwinds (11,000 daily Medicare-eligible individuals). Agent count growth expected, but priority on productivity.
- **Medicare Dynamics**: Shift from Medicare Advantage to Supplement benefits CNO, with higher-net-worth customers cross-selling other products. Medicare Advantage fees not material to results.
- **Investment Strategy**: CFO reaffirmed 6%-7% new money yield target, with cautious allocation to higher-yielding assets. Software exposure limited to $250 million, focused on enterprise software with strong credit support.
- **Bermuda Reinsurance**: Second treaty completed in Q4 2025; no additional transactions planned for 2026, but process respects regulatory timelines.


CNO Financial Group, Inc. (CNO) Q4 2025 Earnings Call Transcript

- **Record Sales Growth**: Q3 NAP up 26% to $125M, driven by 56% D2C life insurance growth and 23% health insurance expansion.
- **Strategic Restructuring**: $20M annual loss fee services business exited, freeing capital for core insurance and share buybacks.
- **ROE Target Hike**: 2027 operating ROE target raised to +200bps vs. 2024, with 50bps from fee exit and Bermuda treaty.
- **Investment Strength**: 11 consecutive quarters of new money rates >6%, supporting 7% net investment income growth.

**【CEO Opening Remarks】**
- Q3 2025 total new annualized premiums reached $125 million, up 26% YoY, driven by double-digit growth in both Consumer and Worksite divisions.
- Record D2C life insurance sales of $125 million (+56% YoY) due to non-TV marketing (72% of leads) and strategic partnerships.
- Exit of Worksite fee services business (Web Benefits Design and DirectPath) to focus on core insurance operations, with exit process expected to complete by mid-2026.
- 13th consecutive quarter of producing agent comp growth and 11th consecutive quarter of agent count growth.

**【CFO Financial Highlights】**
- Operating EPS of $1.29 (+16% YoY), driven by strong investment results (11 consecutive quarters of new money rates >6%) and cost discipline.
- GAAP net income of $420 million and Non-GAAP EPS of $1.08 exceeded expectations.
- $96.7 million impairment charge on fee services business goodwill, with additional $15-20 million exit costs expected in Q4 2025.
- Updated 2027 operating ROE target raised to +200bps vs. 2024 run rate (from prior +150bps), with 50bps incremental improvement from fee services exit and Bermuda treaty.
- Excess capital deployment: $76 million in Q3 share buybacks, $310 million YTD, with 8% reduction in diluted shares outstanding.

**【Q&A Key Highlights】**
1. **D2C Sales Growth**: CEO emphasized selective partnerships (e.g., Hispanic market) and shifting marketing mix away from TV. Q4 D2C growth expected to moderate due to seasonal trends.
2. **Fee Services Exit Impact**: CFO noted $20 million annual pretax loss elimination and no material impact on Worksite insurance sales. Cash flow impact aligns with GAAP results.
3. **Bermuda Treaty Expansion**: CFO exploring life insurance cessions to diversify product mix, with no immediate statutory impacts.
4. **Medicare Trends**: Actuary confirmed 10% rate increase filings, with continued shift from Medicare Advantage to Supplement plans (+33% Medicare Supplement sales YoY).

CNO Financial Group, Inc. (CNO) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Total new annualized premiums up 17% YoY, annuity sales hit $500M (19% YoY), and brokerage assets reached $4.6B (27% YoY).
- **Digital Dominance**: Web/digital D2C sales up 39% YoY, 89% instant underwriting decisions on life policies.
- **Financial Strength**: Operating ROE of 11.8%, new money rates >6%, and 10.5% full-year ROE target on track.
- **Medicare Resilience**: Stable Med Supp margins, captive agent model mitigates churn, and 10% rate filings offset claims trends.
- **Investment Focus**: High-yield assets (residential mortgages, CRE CDOs) and alternative investments at 6% vs. 9-10% target.

**【CEO Summary Section】**
- **Record Sales Growth**: Total new annualized premiums reached $120 million, up 17% YoY, driven by double-digit growth across all product lines. Annuity collected premiums hit a record $500 million, up 19% YoY.
- **Agent Productivity**: Producing agent count increased by 3% (10th consecutive quarter of growth), with registered agents up 6%. Life insurance sales via D2C channels rose 29% YoY.
- **Digital Expansion**: Web and digital sales accounted for 30% of D2C leads, up 39% YoY, with 89% instant underwriting decisions on simplified life products.
- **Medicare Segment Strength**: Brokerage and advisory client assets reached $4.6 billion (up 27%), while Medicare Supplement sales maintained stable margins despite industry challenges.

**【CFO Financial Commentary】**
- **Earnings Performance**: Operating EPS of $0.87, with operating ROE of 11.8% (11.2% excluding AOCI), on track for 10.5% full-year target.
- **Investment Results**: Net investment income up 2%, with new money rates exceeding 6% for 10 consecutive quarters. Book yield grew 11bps YoY to 4.92%.
- **Capital Management**: $100 million share buybacks reduced diluted shares by 8%, with RBC ratio at 378% (target 375%). Free cash flow guidance remains $200-250 million.

**【Q&A Highlights】**
- **D2C Sales Momentum**: Digital channels now 30% of D2C leads, with 39% YoY growth. Management expects sustained growth despite TV ad decline.
- **Medicare Risk Mitigation**: Captive agent model reduces churn, Med Supp repricing (10% rate filings) offsets claims trends. No direct exposure to Medicare Advantage underwriting risks.
- **Investment Opportunities**: Focus on residential mortgages (100-150bps over single-A), CRE CDOs, and taxable munis. Alternative investments yield 6% vs. 9-10% long-term target.
- **Agent Recruitment**: 12th consecutive quarter of NAP growth in Worksite division, with 34% increase in recruiting and 16% productivity gains.


CNO Financial Group, Inc. (CNO) Q2 2025 Earnings Call Transcript

- **EPS Growth**: Operating EPS up 52% to $0.79, driven by annuity and Medicare sales growth.
- **Medicare Momentum**: Medicare Supplement NAP +24%, Medicare Advantage policies +42% despite fee timing volatility.
- **Capital Strength**: RBC ratio 379%, $250M liquidity, and $100M Q1 buybacks.
- **Strategic Initiatives**: Launch of Optavise Clear platform and digital channel diversification (36% of D2C leads).
- **Resilience**: Stress tests confirm ability to navigate recession without breaching capital targets.

**【CEO Summary Section】**
- **Strong Q1 Performance**: Operating EPS rose 52% to $0.79, driven by growth in annuities, health products, and Medicare solutions. Annuity collected premiums increased 12%, while Medicare Supplement NAP grew 24%.
- **Division Highlights**: 
  - **Consumer Division**: Brokerage/advisory assets up 16%, annuity account values +7%, and health NAP +9%. Long-term care NAP declined on a strong prior comp.
  - **Worksite Division**: Insurance sales up 11% (12th consecutive quarter), with critical illness up 37% and life insurance +17%. New group client NAP rose 134%.
- **Agent Growth**: Producing agent count up 2% (9th straight quarter), with Worksite agents +8% (11th consecutive quarter).
- **Strategic Initiatives**: Launch of Optavise Clear platform combining benefits advocacy and Medicare services. Accelerated underwriting delivers 87% instant decision rate.

**【CFO Financial Commentary】**
- **Financial Metrics**: GAAP net income $132 million, operating EPS +42% to $0.79. Fee income impacted by Medicare Advantage accounting rules, but underlying sales +42%.
- **Investment Performance**: New money rate 6.43% (9th consecutive quarter above 6%). Book yield up 17bps to 4.87%, net investment income +6%.
- **Capital Management**: $100M share buybacks, reducing diluted shares 7%. RBC ratio 379%, well above target. Capital deployment focused on high-quality fixed income.
- **Guidance**: Full-year 2025 and 3-year ROE targets reaffirmed. Stress tests show ability to withstand severe recession without breaching capital thresholds.

**【Q&A Key Highlights】**
- **Buybacks**: $100M Q1 buybacks; CFO expects continued elevated levels given $250M Holdco liquidity. 
- **Medicare Advantage**: Fee income timing volatility due to carrier mix, but 42% policy growth signals strong demand. Anticipate partial reversal in future quarters.
- **Market Volatility**: RBC ratio temporarily impacted by FIA derivatives mark-to-market, but economic hedge remains intact. Equity market weakness could persist in Q2.
- **Direct-to-Consumer**: Life sales down due to high TV ad costs, but 36% of leads now from digital channels. Expect second-half recovery.
- **ROE Expansion**: Multiple drivers including expense control, higher rates, and capital efficiency. 150bps improvement target over 2025-2027.


CNO Financial (CNO)-29 Apr 25-2025 Q1 Earnings call transcript

- **Record Growth Across Divisions**: 7% total NAP growth, 16% Worksite insurance sales, and 35% long-term care NAP highlight broad-based expansion.
- **Profitability & Capital Return**: 28% EPS growth, 10% ROE, and $349M capital returns reflect strong financial health.
- **Tech-Driven Future**: $170M tech modernization to enable AI innovation, with 2025 ROE guidance of 10.5% despite one-time costs.
- **Strategic Initiatives**: Geographic expansion, Bermuda reinsurance, and fee-based services drive long-term growth and ROE expansion.
- **Annuity Resilience**: Despite moderating surrenders, strong sales momentum expected to continue amid demographic tailwinds.


**【CEO Summary Section】**
- Total new annualized premium (NAP) grew 7% for the full year, driven by 10% growth in field agent NAP in the Consumer Division and 16% insurance sales growth in the Worksite Division.
- Operating EPS rose 28% to $3.97, with 40% growth excluding significant items. Book value per diluted share increased 10% to $37.19.
- Capital returns totaled $349 million, a 50% increase over 2023, including a 12th consecutive dividend hike.
- Key product line growth: Medicare Advantage policies up 39% Q4, long-term care NAP up 35% annually, and Worksite fee sales up 37%.

**【CFO Financial Commentary】**
- 2024 operating ROE (excluding significant items) reached 10%, with a target to improve by 150 basis points over three years (10.5% in 2025, 11.5% by 2027).
- New money rate exceeded 6% for eight consecutive quarters, averaging 6.72% in Q4.
- 2025 guidance includes $3.70-$3.90 EPS, 19.0-19.4% expense ratio, and $200-250 million excess cash flow to Holdco.
- $170 million three-year tech modernization initiative to enhance AI and cloud capabilities, with $60 million allocated in 2025.

**【Q&A Key Highlights】**
- **Geographic Expansion**: Worksite Division's geographic expansion contributed 38% of Q4 NAP growth, with significant upside in underserved markets.
- **Bermuda Reinsurance**: Exploring additional treaties post successful initial transaction, with focus on long-term growth opportunities.
- **Tech Investment Impact**: $170M tech spend to modernize legacy systems, enabling faster product development and improved customer experience, with costs excluded from operating ROE calculations.
- **ROE Confidence**: Combines sales growth, higher interest rates, and disciplined capital management; 2025 guidance includes 50bp ROE improvement despite one-time tech expenses.
- **Annuity Market**: Strong demand driven by demographics (aging population, lack of pensions), though 2025 growth may face tougher year-over-year comparisons.


Actual											0.58	0.55	0.79	0.61	0.55	0.66	0.72	0.87	0.42	0.85	0.49	0.56	0.51	0.54	0.88	1.18	0.52	1.05	1.11	1.31	0.79	0.87	1.29	1.47
Forecast											0.4023	0.2601	0.5018	0.5928	0.5172	0.5591	0.6144	0.6057	0.5446	0.4756	0.4765	0.5637	0.6137	0.6818	0.7333	0.8522	0.6477	0.7184	0.8229	1.0688	0.79	0.8553	0.916	1.205
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+44.17%	+111.46%	+57.43%	+2.90%	+6.34%	+18.05%	+17.19%	+43.64%	-22.88%	+78.72%	+2.83%	-0.66%	-16.90%	-20.80%	+20.01%	+38.47%	-19.72%	+46.16%	+34.89%	+22.57%	0.00%	+1.72%	+40.83%	+21.99%

CNO

CNO fundamentals

CNO Q4 2025 Earnings

Earnings Call

You can ask Aime

CNO

CNO fundamentals

CNO Q4 2025 Earnings

Earnings Call

CNO Earnings Call Summary for Q4/202511:00 AM on Feb 6, 2026

CNO Earnings Call Summary for Q3/202511:00 AM on Nov 4, 2025

CNO Earnings Call Summary for Q2/202511:00 AM on Jul 29, 2025

CNO Earnings Call Summary for Q1/202511:00 AM on Apr 29, 2025

CNO Earnings Call Summary for Q4/202411:00 AM on Feb 7, 2025

You can ask Aime